drugset / Trial / NCT03798912

A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

NCT03798912

Phase 1 Completed 62 enrolled RANI Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to ascertain the safety, tolerability and performance of the RaniPill capsule in healthy volunteers

Timeline

Start
2019-07-09
Primary completion
2020-02-17
Completion
2020-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 100 ug Intravenous

Indications

No indication recorded.